A class of 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole myricetin compounds and preparation method thereof
By synthesizing myricetin compounds containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole, the problem of the lack of reports on the antiviral activity of this structure in the prior art was solved, and effective inhibition of tobacco mosaic virus was achieved, showing excellent biological activity.
Patent Information
- Application Number
- CN202211455216.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-21
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-11-21
AI Technical Summary
In the prior art, there are no reports on the application of myricetin structures containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole in terms of antiviral activity against plant viruses, and there is limited research on 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole in the field of plant diseases.
A series of myricetin compounds containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole were synthesized. The preparation methods included using formyl hydrazine and carbon disulfide as raw materials to prepare intermediate compounds under alkaline conditions, and reacting them with myricetin derivatives to generate biologically active myricetin derivatives for the prevention and control of agricultural pests and diseases.
At 500 μg/mL, the target compounds showed good inhibitory activity against tobacco mosaic virus, with some compounds exhibiting better inhibition rates than existing agents, demonstrating potential application prospects as antiviral drugs against plants.
Smart Images

Figure CN116082365B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of chemical industry, and in particular to a 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole myricetin derivative, and also relates to a preparation method of the 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole myricetin derivative, and application of the 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole myricetin derivative in antiviral activity. Background Art
[0002] Natural active molecules and their derivatives have unique structures, novel modes of action, low toxicity to humans and animals, and are environmentally friendly, and they are of great significance in the discovery of pesticide lead compounds. Natural products are also called secondary metabolites, such as flavonoids, phenols, terpenes, alkaloids, terpenes, and polysaccharides. Myricetin belongs to the flavonoid class of compounds and is widely present in nature. It also has biological activities such as antibacterial, antiviral, anticancer, anti-inflammatory, and anti-tumor, and plays an important role in the discovery of new drugs and lead compounds.
[0003] In 2021, Peng et al. (Journal of Agricultural and Food Chemistry, 2021, 69, 11085-11094) used the principle of active splicing to introduce active small molecule oxadiazole groups into the structure of myricetin, synthesized a series of myricetin derivatives containing 1,3,4-oxadiazole sulfide, and tested their anti-TMV (tobacco mosaic virus) activity. The test results showed that at 500 μg / mL, it had good inhibitory activity against TMV, and some of the compounds had excellent effects in in vivo treatment, with an inhibition rate better than that of its control agent Ningnanmycin.
[0004] In 2016, Chai et al. (Fine Chemicals, 2016, 33(11), 1244-1249) used myricetin (MYR) as a matrix and reacted it with paraformaldehyde and dimethylamine to obtain the myricetin Mannich alkaloid compound 8-dimethylaminocyclomethylmyricetin (8-MYR). The in vitro antitumor activity of 8-MYR was investigated by Fenton reaction, UV-Vis and MTT methods. The test results showed that compared with MYR, 8-MYR has stronger antitumor activity.
[0005] In 2018, Ruan et al. (Journal of Chemistry in Universities, 2018, 39(6), 1197-1204.) designed and synthesized 13 myricetin derivatives containing piperazinamide, and tested the in vitro antitumor activity of the compounds against human breast cancer cells (MDA-MB-231) using the MTT colorimetric method. The test results showed that at a concentration of 1 μmol / L, it had good inhibitory activity, and the inhibition rate against MDA-MB-231 cancer cells was higher than that of epirubicin hydrochloride.
[0006] In 2020, Jiang et al. (Pest Management Science, 2020, 76, 853-860.) synthesized a series of myricetin derivatives containing sulfonamide groups and studied their antibacterial activity. The results of bioassays showed that at a concentration of 100 μg / mL, some of the synthesized compounds had good in vitro antibacterial activity against citrus canker and rice bacterial blight, and their inhibitory activity was much better than that of the control agent thiophanate-copper.
[0007] In 2017, Xiao et al. (Journal of Chemistry in Universities 2017, 38(1), 35-40.) reported a series of amide myricetin derivatives and tested their inhibitory activity against Xanthomonas oryzae, citrus canker and tobacco bacterial wilt. The test results showed that the compounds had certain inhibitory activity against the three tested bacteria. The results showed that at 200 μg / mL, the inhibitory activity of some compounds against Xanthomonas oryzae and tobacco bacterial wilt was 100%.
[0008] 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole, as a class of thiadiazole derivatives, also exhibits good biological activity. It is mainly reflected in medical antibacterial and antifungal drugs, but it is rarely used in the field of plant diseases, so its synthesis research has attracted much attention. Therefore, 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole is one of the resources worthy of attention in the future research and development of new drugs, and has great development prospects.
[0009] In summary, compounds containing myricetin and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole have good biological activities, but there are no reports on the anti-plant virus activity of myricetin containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole. Summary of the invention
[0010] The object of the present invention is to overcome the above disadvantages and provide myricetin compounds containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole and their derivatives.
[0011] One of the purposes of the present invention is to provide myricetin compounds containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole.
[0012] Another object of the present invention is to provide an intermediate compound for preparing the above-mentioned compound and a preparation method thereof.
[0013] Another object of the present invention is to provide a composition containing the above compound.
[0014] Another object of the present invention is to provide the use of the above compounds.
[0015] Another object of the present invention is to provide a method for controlling agricultural pests and diseases using the above compounds.
[0016] To achieve the above object, the present invention adopts the following technical solutions:
[0017] A myricetin compound containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole, wherein the compound has a structure as shown in general formula A:
[0018]
[0019] in,
[0020] R is independently selected from one or more of optionally substituted or unsubstituted alkyl, optionally substituted or unsubstituted alkenyl, optionally substituted or unsubstituted alkynyl, optionally substituted or unsubstituted alkoxy, optionally substituted or unsubstituted cycloalkyl, optionally substituted or unsubstituted aryl, and optionally substituted or unsubstituted heteroaryl;
[0021] n is independently selected from 3 or 4.
[0022] 2. The myricetin compound containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole according to claim 1, characterized in that:
[0023] Preferably, R is independently selected from one or more of an alkyl group, an alkoxy group, a substituted or unsubstituted aryl group; more preferably, R is independently selected from a C1-C6 alkyl group, a C1-C6 alkoxy group, a substituted or unsubstituted C6-C 15 One or more of the aryl groups, wherein the substitution refers to substitution by C1-C6 alkyl, C1-C6 alkoxy; most preferably, R is independently selected from phenyl, chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl, dibromophenyl, difluorophenyl, nitrophenyl, dinitrophenyl, methoxyphenyl, dimethoxyphenyl, methylphenyl, dimethylphenyl, aminophenyl, hydroxyphenyl, benzyl, o-fluorobenzyl, m-fluorobenzyl, p-fluorobenzyl, o-bromobenzyl, m-bromobenzyl, p-bromobenzyl, o-chlorobenzyl, m-chlorobenzyl, p-chlorobenzyl, one or more; further preferably selected from the following compounds:
[0024]
[0025]
[0026] The present invention also provides an intermediate compound for preparing the myricetin compound containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole, as shown in the following formula:
[0027]
[0028] where n is as described above.
[0029] The present invention provides a method for preparing the myricetin compound containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole, which is characterized by comprising the following steps:
[0030]
[0031] Preferably, the method further comprises the following steps:
[0032]
[0033] More preferably, the method comprises the following steps:
[0034]
[0035] Most preferably, the following steps are included:
[0036]
[0037]
[0038] The present invention provides a composition, characterized by containing the compound and an adjuvant or fungicide, insecticide or herbicide applicable in agriculture.
[0039] The present invention provides the use of the compound or the composition in preventing and controlling agricultural pests and diseases. Preferably, the agricultural pests and diseases are plant viral diseases; more preferably, the agricultural pests and diseases are tobacco mosaic disease, cucumber mosaic disease and tomato mosaic disease;
[0040] The present invention provides a method for preventing and controlling agricultural pests and diseases, wherein the compound or the composition acts on harmful substances or their living environment; preferably, the agricultural pests and diseases are plant pathogenic bacteria diseases; more preferably, the agricultural pests and diseases are tobacco mosaic disease, cucumber mosaic disease and tomato mosaic disease.
[0041] The present invention provides a method for protecting plants from agricultural pests and diseases, which comprises a method step in which the plants are contacted with the compound or the composition.
[0042] More preferably, the present invention also provides a method for preparing the compound:
[0043] Its synthetic route is as follows:
[0044] (1) Using formic hydrazide and carbon disulfide as raw materials, 2-acetylhydrazide-1-potassium dithiocarbonate (intermediate 1) was prepared under alkaline conditions:
[0045]
[0046] (2) Using 80% hydrazine hydrate and 2-acetylhydrazine-1-dithiocarbonate potassium as raw materials, 4-amino-5-methyl-4H-1,2,4-triazole-3-thiol (intermediate 2) was prepared under alkaline conditions:
[0047]
[0048] (3) Using 4-amino-5-methyl-4H-1,2,4-triazole-3-thiol and carbon disulfide as raw materials, 3-methyl-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol (intermediate 3) was prepared:
[0049]
[0050] (4) Using iodomethane and 5,7-dihydroxy-3-(((2R, 3S, 4S, 5S, 6R)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-(3,4,5-trihydroxyphenyl)-4H-chromone-4-one as raw materials, 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (Intermediate 4) was prepared:
[0051]
[0052] (5) Using dibromoalkane and 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one as raw materials and N,N-dimethylformamide (DMF) as solvent, 3-(bromomethoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (Intermediate 5) was prepared:
[0053]
[0054] Compared with the prior art, the present invention has obvious beneficial effects. It can be seen from the above technical scheme that the present invention uses formic hydrazide and carbon disulfide as raw materials to prepare 2-acetylhydrazine-1-dithiocarbonate potassium under alkaline conditions, uses 80% hydrazine hydrate and 2-acetylhydrazine-1-dithiocarbonate potassium as raw materials to prepare 4-amino-5-methyl-4H-1,2,4-triazole-3-thiol under alkaline conditions, uses 4-amino-5-methyl-4H-1,2,4-triazole-3-thiol and carbon disulfide as raw materials to prepare 3-methyl-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol, and 5,7-dihydroxy-3-(((2R, 3S, 4S, 5S, 6R)-3,4,5-trihydroxy-6- Methyltetrahydro-2H-pyran-2-yl)oxy)-2-(3,4,5-trihydroxyphenyl)-4H-chromone-4-one is reacted with iodomethane, desugared and methyl protected to generate 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one, and 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one is reacted with dibromoalkane to generate 3-(bromomethoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one. This preparation method uses substituted formyl hydrazide and carbon disulfide, myricetin, and iodomethane as raw materials, which are all common organic reagents and solvents, and the raw materials are easily available. Moreover, the method can react at room temperature or under heating conditions, the reaction conditions are mild, the post-treatment is simple, and the yield is high, which can reach between 41% and 59%.
[0055] The present invention uses 3-(bromomethoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one to react with 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole containing a substituent having excellent biological activity to generate a myricetin derivative containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole. The anti-plant virus activity of the target compound was determined at a concentration of 500 μg / mL. The antibacterial activity test results show that: at the experimental test concentration, it has good inhibitory activity against tobacco mosaic virus and can be used to prepare an anti-plant virus agent. DETAILED DESCRIPTION
[0056] Example 1
[0057] The synthesis of 3-(3-([1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-ylthio)propoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A1) comprises the following steps:
[0058] (1) Synthesis of potassium 2-formylhydrazide-1-dithiocarbonate: Potassium hydroxide (5.0 g) was added to 30 mL of ethanol and stirred in an ice bath for about 30 min. Then, formylhydrazide (3.3 g) was added to the system. After the addition of carbon disulfide was completed, the ice bath was removed and the mixture was stirred at room temperature for about 2 h. After the reaction was completed, the reaction mixture was filtered and the filter cake was washed three times with ethanol to obtain a white solid with a yield of 78.6%.
[0059] (2) Synthesis of 4-amino-4H-1,2,4-triazole-3-thiol: Potassium 2-carboxyhydrazide-1-dithiocarbonate (5.0 g) was added to 40 mL of 80% hydrazine hydrate and stirred for about 20 min until all the solid was dissolved. The temperature was slowly raised to reflux. After reacting for about 20 h, the system was transferred to a 500 mL beaker and an appropriate amount of ice water was added. The pH of the system was then adjusted to about 2 to 3 with a 5% dilute hydrochloric acid solution. A large amount of white solid precipitated. The solid was filtered and the filter cake was recrystallized with ethanol to obtain a white solid with a yield of 56.3%.
[0060] (3) Synthesis of [1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: Potassium hydroxide (3.0 g) and 30 mL of methanol were added to a 100 mL three-necked flask, and stirred for about 10 min. The reaction system was placed in an ice bath for about 30 min, and 4-amino-4H-1,2,4-triazole-3-thiol (3.5 g) was added to the system. After stirring evenly, the mixture was heated under reflux. The reaction was completed after about 15 h. The system was transferred to a 500 mL beaker and an appropriate amount of ice water was added. The pH of the system was then adjusted to about 2-3 with a 5% dilute hydrochloric acid solution. A large amount of white solid precipitated. The solid was filtered and the filter cake was recrystallized with ethanol to obtain a white solid with a yield of 61.5%.
[0061] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: In a 100-ml three-necked flask, 5,7-dihydroxy-3-(((2R, 3S, 4S, 5S, 6R)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-(3,4,5-trihydroxyphenyl)-4H-chromone-4-one (3.9 g), anhydrous potassium carbonate (2.3 g) and 30 mL of DMF were added. After stirring for about 10 min, iodomethane (2.6 mL) was added to the system. The reaction was allowed to proceed for about 2 d. The filtrate was collected by suction and dispersed with water and washed with dichloromethane. The organic phase was collected and the solvent was removed by distillation under reduced pressure. Add 40 mL of ethanol to the concentrate and heat to reflux. After about 1 h, add 7.5 mL of concentrated hydrochloric acid, and solid precipitates. Continue reflux reaction for about 2.5 h. Cool the reaction solution, filter it with suction, and wash the filter cake with ethanol several times to obtain a yellow solid with a yield of 83.1%.
[0062] (5) Synthesis of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: 3-Hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (3.0 g) and anhydrous potassium carbonate (2.1 g) were placed in 30 mL of DMF and stirred. After the reaction system was ice-bathed for about 1 hour, 1,3-dibromopropane (1.6 mL) was added and the reaction was continued for about 6 hours. The system was dispersed with 200 mL of ice water, and the precipitated solid was filtered. The filter cake was washed with water and petroleum ether several times to obtain a white solid with a yield of 92.5%.
[0063] (6) Synthesis of 3-(3-([1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-ylthio)propoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: 3-(bromomethoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (0.8 g), 4-amino-5-methyl-4H-1,2,4-triazole-3-thiol (0.4 g), anhydrous potassium carbonate (0.5 g) and DMF (30 mL) were stirred at room temperature. The reaction was completed after about 5 hours. The reaction system was dispersed with 200 mL of deionized water to precipitate a solid. The crude product was filtered out and subjected to column chromatography to obtain a white solid with a yield of 65.7%.
[0064] Example 2
[0065] 3-(4-([1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-ylthio)butoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A2), comprising the following steps:
[0066] (1) Synthesis of potassium 2-formylhydrazide-1-dithiocarbonate: as in step (1) of Example 1.
[0067] (2) Synthesis of 4-amino-4H-1,2,4-triazole-3-thiol: as in step (2) of Example 1.
[0068] (3) Synthesis of [1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: as in step (3) of Example 1.
[0069] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0070] (5) Synthesis of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: As in step (5) of Example 1, except that 1,4-dibromobutane is used as the raw material.
[0071] (6) Synthesis of 3-(4-([1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-ylthio)butoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one is used as the raw material.
[0072] Example 3
[0073] The synthesis of 5,7-dimethoxy-3-(3-((3-methyl-[1,2,4]triazol[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A3) comprises the following steps:
[0074] (1) Synthesis of potassium 2-acetylhydrazine-1-dithiocarbonate: As in step (1) of Example 1, except that acetylhydrazine is used as the raw material.
[0075] (2) Synthesis of 4-amino-5-methyl-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-acetylhydrazine-1-potassium dithiocarbonate is used as the raw material.
[0076] (3) Synthesis of 3-methyl-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-methyl-4H-1,2,4-triazole-3-thiol was used as the raw material.
[0077] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0078] (5) Synthesis of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (5) of Example 1.
[0079] (6) Synthesis of 5,7-dimethoxy-3-(3-((3-methyl-[1,2,4]triazol[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: As in step (6) of Example 1, except that 3-methyl-[1,2,4]triazol[3,4-b][1,3,4]thiadiazol-6-thiol and 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one are used as raw materials.
[0080] Example 4
[0081] The synthesis of 5,7-dimethoxy-3-(4-((3-methyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A4) comprises the following steps:
[0082] (1) Synthesis of potassium 2-acetylhydrazine-1-dithiocarbonate: As in step (1) of Example 1, except that acetylhydrazine is used as the raw material.
[0083] (2) Synthesis of 4-amino-5-methyl-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-acetylhydrazine-1-potassium dithiocarbonate is used as the raw material.
[0084] (3) Synthesis of 3-methyl-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-methyl-4H-1,2,4-triazole-3-thiol was used as the raw material.
[0085] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: As in step (4) of Example 1, except that 1,4-dibromobutane is used as the raw material.
[0086] (5) Synthesis of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: As in step (5) of Example 1, except that 1,4-dibromobutane is used as the raw material.
[0087] (6) Synthesis of 5,7-dimethoxy-3-(4-((3-methyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: As in step (6) of Example 1, except that 3-methyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-thiol is used as the raw material.
[0088] Example 5
[0089] The synthesis of 3-(3-((3-ethyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A5) comprises the following steps:
[0090] (1) Synthesis of 2-propionylhydrazide-1-potassium dithiocarbonate: As in step (1) of Example 1, except that the raw material is propionylhydrazide.
[0091] (2) Synthesis of 4-amino-5-ethyl-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that the raw material is 2-propionylhydrazide-1-potassium dithiocarbonate.
[0092] (3) Synthesis of 3-ethyl-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that the starting material is 4-amino-5-ethyl-4H-1,2,4-triazole-3-thiol.
[0093] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0094] (5) Synthesis of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (5) of Example 1.
[0095] (6) Synthesis of 3-(3-((3-ethyl-[1,2,4]triazol[3,4-b][1,3,4]thiadiazole-6-yl)thio)propoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-ethyl-[1,2,4]triazol[3,4-b][1,3,4]thiadiazole-6-thiol is used as the raw material.
[0096] Example 6
[0097] The synthesis of 3-(4-((3-ethyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A6) comprises the following steps:
[0098] (1) Synthesis of 2-propionylhydrazide-1-potassium dithiocarbonate: As in step (1) of Example 1, except that the raw material is propionylhydrazide.
[0099] (2) Synthesis of 4-amino-5-ethyl-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that the raw material is 2-propionylhydrazide-1-potassium dithiocarbonate.
[0100] (3) Synthesis of 3-ethyl-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that the starting material is 4-amino-5-ethyl-4H-1,2,4-triazole-3-thiol.
[0101] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0102] (5) Synthesis of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: As in step (5) of Example 1, except that 1,4-dibromobutane is used as the raw material.
[0103] (6) Synthesis of 1-(2-(2,4-di-chlorobenzyloxy)phenyl)-3-(2-quinoxalinyl)-5-(2-pyridyl)-1,4-pentadien-3-one oxime ether: As described in step (6) of Example 1, except that 3-ethyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole-6-thiol and 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one are used as raw materials.
[0104] Example 7
[0105] The synthesis of 5,7-dimethoxy-3-(3-((methoxymethyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A7) comprises the following steps:
[0106] (1) Synthesis of 2-(2-methoxyacetyl)hydrazine-1-potassium dithiocarbonate: As in step (1) of Example 1, except that 2-methoxyacetylhydrazine is used as the raw material.
[0107] (2) Synthesis of 4-amino-5-(methoxymethyl)-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-(2-methoxyacetyl)hydrazine-1-potassium dithiocarbonate is used as the raw material.
[0108] (3) Synthesis of 3-(methoxymethyl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-(methoxymethyl)-4H-1,2,4-triazole-3-thiol is used as the raw material.
[0109] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0110] (5) Synthesis of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (5) of Example 1.
[0111] (6) Synthesis of 5,7-dimethoxy-3-(3-((methoxymethyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-(methoxymethyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-thiol is used as the raw material.
[0112] Example 8
[0113] The synthesis of 5,7-dimethoxy-3-(4-((3-(methoxymethyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A8) comprises the following steps:
[0114] (1) Synthesis of 2-(2-methoxyacetyl)hydrazine-1-potassium dithiocarbonate: As in step (1) of Example 1, except that 2-methoxyacetylhydrazine is used as the raw material.
[0115] (2) Synthesis of 4-amino-5-(methoxymethyl)-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-(2-methoxyacetyl)hydrazine-1-potassium dithiocarbonate is used as the raw material.
[0116] (3) Synthesis of 3-(methoxymethyl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-(methoxymethyl)-4H-1,2,4-triazole-3-thiol is used as the raw material.
[0117] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0118] (5) Synthesis of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: As in step (5) of Example 1, except that 1,4-dibromobutane is used as the raw material.
[0119] (6) Synthesis of 5,7-dimethoxy-3-(4-((3-(methoxymethyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-(methoxymethyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-thiol and 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one are used as raw materials.
[0120] Example 9
[0121] The synthesis of 5,7-dimethoxy-3-(3-((3-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A9) comprises the following steps:
[0122] (1) Synthesis of 2-benzoylhydrazide-1-potassium dithiocarbonate: As in step (1) of Example 1, except that benzoylhydrazide is used as the raw material.
[0123] (2) Synthesis of 4-amino-5-phenyl-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-benzoylhydrazide-1-potassium dithiocarbonate is used as the raw material.
[0124] (3) Synthesis of 3-phenyl-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-phenyl-4H-1,2,4-triazole-3-thiol was used as the raw material.
[0125] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0126] (5) Synthesis of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (5) of Example 1.
[0127] (6) Synthesis of 5,7-dimethoxy-3-(3-((3-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-thiol is used as the raw material.
[0128] Example 10
[0129] The synthesis of 5,7-dimethoxy-3-(4-((3-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A9) comprises the following steps:
[0130] (1) Synthesis of 2-benzoylhydrazide-1-potassium dithiocarbonate: As in step (1) of Example 1, except that benzoylhydrazide is used as the raw material.
[0131] (2) Synthesis of 4-amino-5-phenyl-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-benzoylhydrazide-1-potassium dithiocarbonate is used as the raw material.
[0132] (3) Synthesis of 3-phenyl-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-phenyl-4H-1,2,4-triazole-3-thiol was used as the raw material.
[0133] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0134] (5) Synthesis of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: As in step (5) of Example 1, except that 1,4-dibromobutane is used as the raw material.
[0135] (6) Synthesis of 5,7-dimethoxy-3-(4-((3-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-thiol and 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one are used as raw materials.
[0136] Embodiment 11
[0137] The synthesis of 5,7-dimethoxy-3-(3-(p-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A11) comprises the following steps:
[0138] (1) Synthesis of 2-(4-methylbenzoyl)hydrazine-1-potassium dithiocarbonate: As in step (1) of Example 1, except that 4-methylbenzoylhydrazine is used as the raw material.
[0139] (2) Synthesis of 4-amino-5-(p-tolyl)-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-(4-methylbenzoyl)hydrazine-1-potassium dithiocarbonate is used as the raw material.
[0140] (3) Synthesis of 3-(p-tolyl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-(p-tolyl)-4H-1,2,4-triazole-3-thiol is used as the raw material.
[0141] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0142] (5) Synthesis of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (5) of Example 1.
[0143] (6) Synthesis of 5,7-dimethoxy-3-(3-(p-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole-6-yl)thio)propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-(p-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole-6-thiol is used as the raw material.
[0144] Example 12
[0145] The synthesis of 5,7-dimethoxy-3-(4-((3-(p-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A12) comprises the following steps:
[0146] (1) Synthesis of 2-(4-methylbenzoyl)hydrazine-1-potassium dithiocarbonate: As in step (1) of Example 1, except that 4-methylbenzoylhydrazine is used as the raw material.
[0147] (2) Synthesis of 4-amino-5-(p-tolyl)-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-(4-methylbenzoyl)hydrazine-1-potassium dithiocarbonate is used as the raw material.
[0148] (3) Synthesis of 3-(p-tolyl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-(p-tolyl)-4H-1,2,4-triazole-3-thiol is used as the raw material.
[0149] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0150] (5) Synthesis of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: As in step (5) of Example 1, except that 1,4-dibromobutane is used as the raw material.
[0151] (6) Synthesis of 5,7-dimethoxy-3-(4-((3-(p-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-(p-methylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-thiol and 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one are used as raw materials.
[0152] Example 13
[0153] The synthesis of 5,7-dimethoxy-3-(3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A13) comprises the following steps:
[0154] (1) Synthesis of potassium 2-(4-methoxybenzoyl)hydrazine-1-dithiocarbonate: As in step (1) of Example 1, except that 4-methoxybenzohydrazine is used as the raw material.
[0155] (2) Synthesis of 4-amino-5-(4-methoxyphenyl)-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-(4-methoxybenzoyl)hydrazine-1-potassium dithiocarbonate is used as the raw material.
[0156] (3) Synthesis of 3-(4-methoxyphenyl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-(4-methoxyphenyl)-4H-1,2,4-triazole-3-thiol is used as the raw material.
[0157] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0158] (5) Synthesis of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (5) of Example 1.
[0159] (6) Synthesis of 5,7-dimethoxy-3-(3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-thiol is used as the raw material.
[0160] Embodiment 14
[0161] The synthesis of 5,7-dimethoxy-3-(4-(3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A14) comprises the following steps:
[0162] (1) Synthesis of potassium 2-(4-methoxybenzoyl)hydrazine-1-dithiocarbonate: As in step (1) of Example 1, except that 4-methoxybenzohydrazine is used as the raw material.
[0163] (2) Synthesis of 4-amino-5-(4-methoxyphenyl)-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-(4-methoxybenzoyl)hydrazine-1-potassium dithiocarbonate is used as the raw material.
[0164] (3) Synthesis of 3-(4-methoxyphenyl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-(4-methoxyphenyl)-4H-1,2,4-triazole-3-thiol is used as the raw material.
[0165] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0166] (5) Synthesis of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: As in step (5) of Example 1, except that 1,4-dibromobutane is used as the raw material.
[0167] (6) Synthesis of 5,7-dimethoxy-3-(4-(3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-thiol and 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one are used as raw materials.
[0168] Embodiment 15
[0169] The synthesis of 3-(3-((3-(4-(tert-butyl)phenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A15) comprises the following steps:
[0170] (1) Synthesis of potassium 2-(4-(tert-butyl)benzoyl)hydrazine-1-dithiocarbonate: As in step (1) of Example 1, except that 4-(tert-butyl)benzoylhydrazine is used as the raw material.
[0171] (2) Synthesis of 4-amino-5-(4-(tert-butyl)phenyl)-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-(4-(tert-butyl)benzoyl)hydrazine-1-potassium dithiocarbonate is used as the raw material.
[0172] (3) Synthesis of 3-(4-(tert-butyl)phenyl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-(4-(tert-butyl)phenyl)-4H-1,2,4-triazole-3-thiol was used as the raw material.
[0173] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0174] (5) Synthesis of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (5) of Example 1.
[0175] (6) Synthesis of 3-(3-((3-(4-(tert-butyl)phenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-(4-(tert-butyl)phenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-thiol is used as the raw material.
[0176] Example 16
[0177] The synthesis of 3-(4-((3-(4-tert-butyl)phenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A16) comprises the following steps:
[0178] (1) Synthesis of potassium 2-(4-(tert-butyl)benzoyl)hydrazine-1-dithiocarbonate: As in step (1) of Example 1, except that 4-(tert-butyl)benzoylhydrazine is used as the raw material.
[0179] (2) Synthesis of 4-amino-5-(4-(tert-butyl)phenyl)-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-(4-(tert-butyl)benzoyl)hydrazine-1-potassium dithiocarbonate is used as the raw material.
[0180] (3) Synthesis of 3-(4-(tert-butyl)phenyl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-(4-(tert-butyl)phenyl)-4H-1,2,4-triazole-3-thiol was used as the raw material.
[0181] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0182] (5) Synthesis of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: As in step (5) of Example 1, except that 1,4-dibromobutane is used as the raw material.
[0183] (6) Synthesis of 3-(4-((3-(4-tert-butyl)phenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-(4-(tert-butyl)phenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-thiol and 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one are used as raw materials.
[0184] Embodiment 17
[0185] The synthesis of 3-(3-(4-chlorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A17) comprises the following steps:
[0186] (1) Synthesis of 2-(4-chlorobenzoyl)hydrazine-1-potassium dithiocarbonate: As in step (1) of Example 1, except that 4-chlorobenzoylhydrazide is used as the raw material.
[0187] (2) Synthesis of 4-amino-5-(4-chlorophenyl)-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-(4-chlorobenzoyl)hydrazine-1-potassium dithiocarbonate is used as the raw material.
[0188] (3) Synthesis of 3-(4-chlorophenyl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-(4-chlorophenyl)-4H-1,2,4-triazole-3-thiol is used as the raw material.
[0189] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0190] (5) Synthesis of 3-(3-bromopropoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (5) of Example 1.
[0191] (6) Synthesis of 3-(3-(4-chlorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)propoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (6) of Example 1, except that 3-(4-chlorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-thiol is used as the raw material.
[0192] Embodiment 18
[0193] The synthesis of 3-(4-((3-(4-chlorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one (compound number A18) comprises the following steps:
[0194] (1) Synthesis of 2-(4-chlorobenzoyl)hydrazine-1-potassium dithiocarbonate: As in step (1) of Example 1, except that 4-chlorobenzoylhydrazide is used as the raw material.
[0195] (2) Synthesis of 4-amino-5-(4-chlorophenyl)-4H-1,2,4-triazole-3-thiol: As in step (2) of Example 1, except that 2-(4-chlorobenzoyl)hydrazine-1-potassium dithiocarbonate is used as the raw material.
[0196] (3) Synthesis of 3-(4-chlorophenyl)-[1,2,4]triazole[3,4-b][1,3,4]thiadiazole-6-thiol: As in step (3) of Example 1, except that 4-amino-5-(4-chlorophenyl)-4H-1,2,4-triazole-3-thiol is used as the raw material.
[0197] (4) Synthesis of 3-hydroxy-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as in step (4) of Example 1.
[0198] (5) Synthesis of 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: As in step (5) of Example 1, except that 1,4-dibromobutane is used as the raw material.
[0199] (6) Synthesis of 3-(4-((3-(4-chlorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-yl)thio)butoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one: as described in step (6) of Example 1, except that 3-(4-chlorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-thiol and 3-(4-bromobutoxy)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-4H-chromone-4-one are used as raw materials.
[0200] The physicochemical properties and mass spectrometry data of the synthesized myricetin derivatives containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole are shown in Table 1. 1 HNMR) and carbon spectra ( 13 C NMR) data are shown in Table 2.
[0201] Table 1 Physicochemical properties of target compounds and their mass spectrometry analysis data
[0202] Compound Yield (%) Characteristics Melting point(℃) HRMS, m / z (calcd.) A1 65.7 White solid 133.2-134.6 <![CDATA[587.1625(587.1624[M+H] + )]]> A2 66.3 White solid 149.3-150.7 <![CDATA[601.1421(602.1416[M+H] + )]]> A3 59.8 White solid 146.7-148.1 <![CDATA[601.1433(601.1421[M+H] + )]]> A4 58.3 White solid 135.5-136.9 <![CDATA[615.1578(615.1572[M+H] + )]]> A5 49.8 White solid 189.1-190.6 <![CDATA[615.1578(615.1574[M+H] + )]]> A6 45.9 White solid 137.3-138.8 <![CDATA[629.1734(629.1729[M+H] + )]]> A7 66.1 White solid 149.2-150.7 <![CDATA[631.1527(631.1524[M+H] + )]]> A8 66.7 Yellow solid 114.0-115.7 <![CDATA[645.1684(645.1678[M+H] + )]]> A9 70.8 Yellow solid 195.1-196.4 <![CDATA[663.1578(663.1577[M+H] + )]]> A10 74.2 White solid 125.5-127.1 <![CDATA[677.1734(677.1731[M+H] + )]]> A11 69.4 White solid 107.9-109.0 <![CDATA[677.1734(677.1728[M+H] + )]]> A12 67.3 White solid 100.1-101.5 <![CDATA[691.1891(691.1887[M+H] + )]]> A13 68.4 White solid 126.3-127.8 <![CDATA[693.1684(693.1678[M+H] + )]]> A14 67.3 White solid 120.3-121.6 <![CDATA[707.1840(707.1830[M+H] + )]]> A15 64.6 White solid 113.4-114.6 <![CDATA[719.2204(719.2196[M+H] + )]]> A16 65.3 White solid 172.1-173.3 <![CDATA[733.2360(733.2354[M+H] + )]]> A17 65.4 White solid 130.1-131.6 <![CDATA[697.1188(697.1183[M+H] + )]]> A18 65.3 White solid 174.6-175.9 <![CDATA[711.1345(711.1339[M+H] + )]]>
[0203] Table 2 H NMR and C NMR data of target compounds
[0204]
[0205]
[0206]
[0207]
[0208] Activity test example 1: Anti-tobacco mosaic virus activity test:
[0209] Test Method
[0210] A. Virus purification
[0211] The Zhou Xueping method (Zhou, XP; Xu, ZX; Xu, J.; Li, DBJ South Chin. Agric. Univ. 1995, 16, 74-79.) was used to select the upper leaves of the host Nicotiana tabacum.L plants that had been inoculated for more than 3 weeks and had TMV systemically infected. The leaves were homogenized in phosphate buffer, filtered through double gauze, centrifuged at 8000r, treated with polyethylene glycol twice, and centrifuged again. The precipitate was suspended in phosphate buffer to obtain the refined liquid of TMV. The entire experiment was carried out at 4°C. The absorbance value at a wavelength of 260nm was measured using an ultraviolet spectrophotometer, and the virus concentration was calculated according to the formula.
[0212] Virus concentration (mg / mL) = (A260 × dilution factor) / E0.1% 1cm 260nm
[0213] Where E represents the extinction coefficient, that is, the light absorption value of a suspension with a concentration of 0.1% (1 mg / mL) at a wavelength of 260 nm when the optical path is 1 cm. The E0.1%1cm260nm of TMV is 5.0.
[0214] B. In vivo therapeutic effects of the agent on TMV infection
[0215] Therapeutic effect of the drug on the infection: Select the heart-leaf tobacco with the same growth of 5-6 leaves, top it, sprinkle corundum evenly on the whole leaf, and use a brush to dip the virus juice (6×10 -3 mg / mL) whole leaves were inoculated with the virus, dried naturally and then rinsed with clean water. After the leaves were dry, the agent was lightly applied to the left half of the leaf with a brush, and the right half of the leaf was coated with a solvent of the corresponding concentration as a control. After 2-4 days, the number of dead spots was recorded and the inhibition rate was calculated according to the following formula.
[0216] C. The protective effect of the agent on TMV infection in vivo
[0217] The protective effect of the agent on TMV infection: Select the heart-leaf tobacco with the same growth of 5-6 leaves to top, and use a brush to gently apply the agent on the left half of the leaf, and apply the solvent of the corresponding concentration on the right half of the leaf as a control. After 24 hours, sprinkle corundum evenly on the whole leaf, and use a brush to dip the virus juice (6×10 -3 mg / mL) whole leaves were inoculated with the virus and rinsed with clean water. The number of dead spots was recorded after 2-4 days, and the inhibition rate was calculated according to the following formula.
[0218] D. The inactivation effect of the agent on TMV infection in vivo
[0219] Mix the agent with an equal volume of virus juice and passivate for 30 minutes. Use a brush to dip the mixture of the agent and the virus, and rub it on the left half of the leaf sprinkled with emery. Use a flat wooden board to support the bottom of the leaf. Mix the sterilized water and virus juice and inoculate the right half of the leaf. Set up 3 plants for each agent treatment, each with 5-6 leaves. Then place the plants in a light incubator to moisturize and culture, control the temperature at 23±1℃, and the light at 10000Lux. After 2-4 days, observe and record the number of dead spots, and calculate the inhibition rate according to the following formula.
[0220] Inhibition rate = (average number of dead spots on the half leaf without the drug - average number of dead spots on the half leaf with the drug) / average number of dead spots on the half leaf without the drug × 100%
[0221] Among them, the average number of necrotic spots on the half leaf without pesticide application and the number of necrotic spots on the half leaf with pesticide application were the average of three repetitions in each group.
[0222] Results of the biological activity test against tobacco mosaic virus
[0223] Table 3 Protective, therapeutic and inactivating activities of target compounds against tobacco mosaic virus
[0224]
[0225]
[0226] Table 4 EC values of some target compounds against tobacco mosaic virus 50 test
[0227]
[0228] The therapeutic, protective and inactivating activities of target compounds A1-A18 against tobacco mosaic virus (TMV) were tested using the half-leaf spot method and the commercial agent Ningnanmycin as the control at a test concentration of 500 μg / mL (see Table 3), as well as the EC 50 The test results showed that the anti-TMV therapeutic activity EC of compounds A2, A5, A6, A8, A9, A12 and A16 was 50 The test results were 162.7, 88.3, 585.8, 139.1, 109.9, 160.1 and 206.9 μg / mL, respectively. Except for compound A6, the EC 50 The values were better than those of Ningnanmycin (227.2 μg / mL). The EC values of the protective activities against TMV of compounds A5, A6, A10, A14, A15, A16 and A18 were 50 The test results were 157.5, 140.0, 103.1, 107.4, 86.3, 79.2 and 111.5 μg / mL, respectively, which were better than the EC of Ningnanmycin. 50 value (179.2μg / mL).
[0229] The above experimental activity data show that myricetin derivatives containing 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole have a certain inhibitory effect on plant viruses (TMV). Some of the target compounds show excellent activity against plant viruses and can be used as potential anti-plant virus drugs with good application prospects.
[0230] To sum up, the above are only preferred embodiments of the present invention and do not limit the present invention in any form. Any simple modification, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.
Claims
1. A 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole myricetin compound, characterized in that: The compound has a structure as shown in general formula A: in, n is independently selected from 3 or 4; R is independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, substituted or unsubstituted C6-C 15 One of the aryl groups; the substituted or unsubstituted C6-C 15 The aryl group is selected from one of phenyl, chlorophenyl, bromophenyl, fluorophenyl, dichlorophenyl, dibromophenyl, difluorophenyl, nitrophenyl, dinitrophenyl, methoxyphenyl, dimethoxyphenyl, methylphenyl, dimethylphenyl, benzyl, o-fluorobenzyl, m-fluorobenzyl, p-fluorobenzyl, o-bromobenzyl, m-bromobenzyl, p-bromobenzyl, o-chlorobenzyl, m-chlorobenzyl and p-chlorobenzyl.
2. The method for preparing a 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazole myricetin compound according to claim 1, characterized in that: The steps include:
3. A composition, characterized in that: Contains the compound according to claim 1, and an agricultural adjuvant or a fungicide, an insecticide or a herbicide.
4. Use of the compound according to claim 1 or the composition according to claim 3 in preventing and controlling agricultural pests and diseases.
5. The use according to claim 4, characterized in that: The agricultural pest is tobacco mosaic virus.
